Review of meningococcal group B vaccines

Clinical Infectious Diseases

Volumn 50, Issue SUPPL. 2, 2010, Pages

  Granoff, Dan M ^a  

^a CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTOXIN; MENINGOCOCCUS VACCINE; OUTER MEMBRANE PROTEIN; PORIN A; RECOMBINANT VACCINE; TUMOR NECROSIS FACTOR ALPHA; BACTERIAL ANTIGEN; BACTERIAL PROTEIN; FACTOR H BINDING PROTEIN, NEISSERIA MENINGITIDIS; FACTOR H-BINDING PROTEIN, NEISSERIA MENINGITIDIS; PORIN; PORIN PROTEINS, NEISSERIA;

BACTERIAL OUTER MEMBRANE; CLINICAL TRIAL; CYTOKINE PRODUCTION; HUMAN; IMMUNOGENICITY; INFECTION PREVENTION; MENINGOCOCCOSIS; PRIORITY JOURNAL; REVIEW; VACCINATION; VACCINE PRODUCTION; EPIDEMIC MENINGITIS; IMMUNOLOGY; MEDICAL RESEARCH; MICROBIOLOGY; NEISSERIA MENINGITIDIS; SECRETORY VESICLE;

ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; BIOMEDICAL RESEARCH; ENDOTOXINS; HUMANS; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP B; PORINS; SECRETORY VESICLES;

EID: 77951646506     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/648966     Document Type: Review

References (129)

1. Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine 2009;27:B51-B63.
2. Trotter CL, Chandra M, Cano R, et al. A surveillance network for meningococcal disease in Europe. FEMS Microbiol Rev 2007; 31: 27-36. (Pubitemid 46058817)
3. Gray SJ, Trotter CL, Ramsay ME, et al. Epidemiology of meningococcal disease in England and Wales 1993/94 to 2003/04: contribution and experiences of the Meningococcal Reference Unit. J Med Microbiol 2006;55:887-896.
4. Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 2004; 364:365-367. (Pubitemid 38970013)
5. Shepard CW, Rosenstein NE, Fischer M. Neonatal meningococcal disease in the United States, 1990 to 1999. Pediatr Infect Dis J 2003;22: 418-422.
6. Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease. N Engl J Med 2001;344:1378-1388.
7. Trotter C, Findlow J, Balmer P, et al. Seroprevalence of bactericidal and anti-outer membrane vesicle antibodies to Neisseria meningitidis group B in England. Clin Vaccine Immunol 2007; 14:863-866.
8. Baker MG, Martin DR, Kieft CE, Lennon D. A 10-year serogroup B meningococcal disease epidemic in New Zealand: descriptive epidemiology, 1991-2000. J Paediatr Child Health 2001;37:S13-S19.
9. Pace D, Pollard AJ, Messonier NE. Quadrivalent meningococcal conjugate vaccines. Vaccine 2009;27:B30-B41.
10. Perrett KP1 Snape MD, Ford KJ, et al. Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants. Pediatr Infect Dis J 2009;28:186-193.
11. Snape MD, Perrett KP, Ford KJ, et al. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. JAMA 2008;299:173-184.
12. Nolan T, Lambert S, Roberton D, et al. A novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y-tetanus-toxoid conjugate vaccine is immunogenic and induces immune memory when co-administered with DTPa-HBV-IPV and conjugate pneumococcal vaccines in infants. Vaccine 2007; 25:8487-8499.
13. Borrow R, Carlone GM, Rosenstein N, et al. Neisseria meningitidis group B correlates of protection and assay standardization-international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005. Vaccine 2006;24:5093-5107.
14. van Alphen L, van den Dobbelsteen G. Meningococcal B vaccine development and evaluation of efficacy. Hum Vaccin 2008;4:158-161. (Pubitemid 351881185)
15. Granoff DM. Relative importance of complement-mediated bactericidal and opsonic activity for protection against meningococcal disease. Vaccine 2009;27(Suppl 2):B117-B125.
16. Granoff DM, Harrison L, Borrow R. Meningoccal Vaccines. In: Plotkin SA, Offit P, Orenstein WA, eds. Vaccines. 5th ed. Philadelphia: Saunders Elsevier, 2008:399-434.
17. Granoff DM, Pollard AJ. Reconsideration of the use of meningococcal polysaccharide vaccine. Pediatr Infect Dis J 2007;26:716-722. (Pubitemid 47424642)
18. Finne J, Leinonen M, Makela PH. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet 1983; 2:355-357.
19. Finne J, Bitter-Suermann D, Goridis C, Finne U. An IgG monoclonal antibody to group B meningococci cross-reacts with developmentall/ regulated polysialic acid units of glycoproteins in neural and extraneural tissues. J Immunol 1987; 138:4402-4407. (Pubitemid 17090418)
20. Jennings HJ, Lugowski C. Immunochemistry of groups A, B, and C meningococcal polysaccharide- tetanus toxoid conjugates. J Immunol 1981;127:1011-1018. (Pubitemid 11051148)
21. Jennings HJ, Gamian A, Ashton FE. N-propionylated group B meningococcal polysaccharide mimics a unique epitope on group B Neisseria meningitidis. J Exp Med 1987;165:1207-1211.
22. Bruge J, Bouveret-Le Cam N, Danve B, Rougon G, Schulz D. Clinical evaluation of a group B meningococcal N-propionylated polysaccharide conjugate vaccine in adult, male volunteers. Vaccine 2004; 22: 1087-1096. (Pubitemid 38296650)
23. Hoist J, Martin D, Arnold R, et al. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine 2009;27(Suppl 2):B3-B12.
24. Fredriksen JH, Rosenqvist E, Wedege E, et al. Production, characterization and control of MenB-vaccine "Folkehelsa": an outer membrane vesicle vaccine against group B meningococcal disease. NIPH Ann 1991;14:67-79; discussion 79-80.
25. Vipond C, Suker J, Jones C, Tang C, Feavers IM, Wheeler JX. Proteomic analysis of a meningococcal outer membrane vesicle vaccine prepared from the group B strain NZ98/254. Proteomics 2006; 6: 3400-3413. (Pubitemid 43886156)
26. Williams JN, Skipp PJ, Humphries HE, Christodoulides M, O'Connor CD, Heckels JE. Proteomic analysis of outer membranes and vesicles from wild-type serogroup B Neisseria meningitidis and a lipopolysaccharide-deficient mutant. Infect Immun 2007;75:1364-1372.
27. Nokleby H, Aavitsland P, O'Hallahan J, Feiring B, Tilman S, Oster P. Safety review: two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease. Vaccine 2007; 25: 3080-3084.
28. Bjune G, Gronnesby JK, Hoiby EA, Closs O, Nokleby H. Results of an efficacy trial with an outer membrane vesicle vaccine against systemic serogroup B meningococcal disease in Norway. NIPH Ann 1991;14:125-130; discussion 130-132.
29. Hoiby EA, Bjune G, Froholm LO, et al. The Norwegian meningococcal serogroup B outer membrane vesicle vaccine protection trials: case tracing, meningococcal antigen detection and serological diagnosis. NIPH Ann 1991;14:107-121; discussion 121-123.
30. de Moraes JC, Perkins BA, Camargo MC, et al. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet 1992;340:1074-1078.
31. Noronha CP, Struchiner CJ, Halloran ME. Assessment of the direct effectiveness of BC meningococcal vaccine in Rio de Janeiro, Brazil: a case-control study. Int J Epidemiol 1995;24:1050-1057.
32. O'Hallahan J, Lennon D, Oster P, et al. From secondary prevention to primary prevention: a unique strategy that gives hope to a country ravaged by meningococcal disease. Vaccine 2005;23:2197-2201. (Pubitemid 40341450)
33. Oster P, Lennon D, O'Hallahan J, Mulholland K, Reid S, Martin D. MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine 2005;23:2191-2196.
34. Kelly C, Arnold R, Galloway Y, O'Hallahan J. A prospective study of the effectiveness of the New Zealand meningococcal B vaccine. Am J Epidemiol 2007; 166:817-823. (Pubitemid 47428901)
35. Galloway Y, Stehr-Green P, McNicholas A, O'Hallahan J. Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years. Int J Epidemiol 2009;38:413-418.
36. Tappero JW, Lagos R, Ballesteros AM, et al. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA 1999;281:1520-1527. (Pubitemid 29200936)
37. Tondella ML, Popovic T, Rosenstein NE, et al. Distribution of Neisseria meningitidis serogroup B serosubtypes and serotypes circulating in the United States. The Active Bacterial Core Surveillance Team. J Clin Microbiol 2000;38:3323-3328.
38. Hoist J. Strategies for development of universal vaccines against meningococcal serogroup B disease: the most promising options and the challenges evaluating them. Hum Vaccin 2007; 3:290-294.
39. Holst J, Feiring B, Naess LM, et al. The concept of "tailor-made, " protein-based, outer membrane vesicle vaccines against meningococcal disease. Vaccine 2005;23:2202-2205.
40. Sandbu S, Feiring B, Oster P, et al. Immunogenicity and safety of a combination of two serogroup B meningococcal outer membrane vesicle vaccines. Clin Vaccine Immunol 2007; 14:1062-1069. (Pubitemid 47518071)
41. Boutriau D, Poolman J, Borrow R, et al. Immunogenicity and safety of three doses of a bivalent (B:4:pl.19,15 and B:4:pl.7-2,4) meningococcal outer membrane vesicle vaccine in healthy adolescents. Clin Vaccine Immunol 2007; 14:65-73.
42. Claassen I, Meylis J, van der Ley P, et al. Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine. Vaccine 1996; 14: 1001-1008.
43. van der Ley P, van der Biezen J, Poolman JT. Construction of Neisseria meningitidis strains carrying multiple chromosomal copies of the porA gene for use in the production of a multivalent outer membrane vesicle vaccine. Vaccine 1995;13:401-407.
44. Rots NY, Kleijne DE. Safety of a nonavalent meningococcal serogroup B vaccine in healthy adult volunteers in a randomised, controlled, single blind study. In: Program and abstracts of the 16th International Pathogenic Neisseria Conference (Rotterdam, The Netherlands). 2008. Abstract P217.
45. de Kleijn ED, de Groot R, Labadie J, et al. Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2-3 and 7-8 years of age. Vaccine 2000; 18:1456-1466. (Pubitemid 30017826)
46. Cartwright K, Morris R, Rumke H, et al. Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins. Vaccine 1999; 17:2612-2619. (Pubitemid 29314456)
47. Peeters CC, Rumke HC, Sundermann LC, et al. Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccine. Vaccine 1996;14:1009-1015.
48. Longworth E, Borrow R, Goldblatt D, et al. Avidity maturation following vaccination with a meningococcal recombinant hexavalent PorA OMV vaccine in UK infants. Vaccine 2002; 20:2592-2596. (Pubitemid 34615600)
49. Martin SL, Borrow R, van der Ley P, Dawson M, Fox AJ, Cartwright KA. Effect of sequence variation in meningococcal PorA outer membrane protein on the effectiveness of a hexavalent PorA outer membrane vesicle vaccine. Vaccine 2000; 18:2476-2481. (Pubitemid 30207032)
50. Russell JE, Jolley KA, Feavers IM, Maiden MC, Suker J. PorA variable regions of Neisseria meningitidis. Emerg Infect Dis 2004; 10:674-678.
51. Sacchi CT, Whitney AM, Popovic T, et al. Diversity and prevalence of PorA types in Neisseria meningitidis serogroup B in the United States, 1992-1998. J Infect Dis 2000;182:1169-1176.
52. Bennett JS, Griffiths DT, McCarthy ND, et al. Genetic diversity and carriage dynamics of Neisseria lactamica in infants. Infect Immun 2005;73:2424-2432.
53. Trotter CL, Gay NJ, Edmunds WJ. The natural history of meningococcal carriage and disease. Epidemiol Infect 2006; 134:556-566.
54. Gorringe AR. Can Neisseria lactamica antigens provide an effective vaccine to prevent meningococcal disease? Expert Rev Vaccines 2005;4:373-379.
55. Weynants VE, Feron CM, Goraj KK, et al. Additive and synergistic bactericidal activity of antibodies directed against minor outer membrane proteins of Neisseria meningitidis. Infect Immun 2007; 75: 5434-5442.
56. Finney M, Vaughan T, Taylor S, et al. Characterization of the key antigenic components and pre-clinical immune responses to a meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles. Hum Vaccin 2008;4:23-30.
57. Oliver KJ, Reddin KM, Bracegirdle P, et al. Neisseria lactamica protects against experimental meningococcal infection. Infect Immun 2002; 70:3621-3526.
58. Gorringe AR, Taylor S, Brookes C, et al. Phase I safety and immunogenicity study of a candidate meningococcal disease vaccine based on Neisseria lastamica outer membrane vesicles. Clin Vaccine Immunol 2009; 16:1113-1120.
59. O'Dwyer C A, Reddin K, Martin D, et al. Expression of heterologous antigens in commensal Neisseria spp.: preservation of conformational epitopes with vaccine potential. Infect Immun 2004;72:6511-6518.
60. Madico G, Welsch JA, Lewis LA, et al. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J Immunol 2006;177:501-510. (Pubitemid 43939163)
61. Masignani V, Comanducci M, Giuliani MM, et al. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med 2003; 197:789-799.
62. Pizza M, Scarlato V, Masignani V, et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 2000;287:1816-1820.
63. Fransen F, Heckenberg SG, Hamstra HJ, et al. Naturally occurring lipid A mutants in Neisseria meningitidis from patients with invasive meningococcal disease are associated with reduced coagulopathy. PLoS Pathog 2009;5:e1000396.
64. Fisseha M, Chen P, Brandt B, Kijek T, Moran E, Zollinger W. Characterization of native outer membrane vesicles from lpxL mutant strains of Neisseria meningitidis for use in parenteral vaccination. Infect Immun 2005; 73:4070-4080.
65. Koeberling O, Giuntini S, Seubert A, Granoff DM. Meningococcal outer membrane vesicle vaccines derived from mutant strains engineered to express factor H binding proteins from antigenic variant groups 1 and 2. Clin Vaccine Immunol 2009;16:156-162.
66. Koeberling O, Seubert A, Granoff DM. Bactericidal antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed factor H-binding protein and genetically attenuated endotoxin. J Infect Dis 2008; 198:262-270.
67. Weynants V, Denoel P, Devos N, et al. Genetically modified L3,7 and L2 lipooligosaccharides from Neisseria meningitidis serogroup B confer a broad cross-bactericidal response. Infect Immun 2009; 77: 2084-2093.
68. Steeghs L, Keestra AM, van Mourik A, et al. Differential activation of human and mouse Toll-like receptor 4 by the adjuvant candidate LpxL1 of Neisseria meningitidis. Infect Immun 2008; 76:3801-3807.
69. Steeghs L, Tommassen J, Leusen JH, van de Winkel JG, van der Ley P. Teasing apart structural determinants of "toxicity" and "adjuvanticity:" implications for meningococcal vaccine development. J Endotoxin Res 2004; 10:113-119.
70. van der Ley P, Steeghs L, Hamstra HJ, ten Hove J, Zomer B, van Alphen L. Modification of lipid A biosynthesis in Neisseria meningitidis lpxL mutants: influence on lipopolysaccharide structure, toxicity, and adjuvant activity. Infect Immun 2001; 69:5981-5990.
71. Rappuoli R, Covacci A. Reverse vaccinology and genomics. Science 2003; 302:602.
72. Litt DJ, Savino S, Beddek A, et al. Putative vaccine antigens from Neisseria meningitidis recognized by serum, antibodies of young children convalescing after meningococcal disease. J Infect Dis 2004; 190: 1488-1497.
73. Moe GR, Zuno-Mitchell P, Hammond SN, Granoff DM. Sequential immunization with vesicles prepared from heterologous Neisseria meningitidis strains elicits broadly protective serum antibodies to group B strains. Infect Immun 2002;70:6021-6031.
74. Hou VC, Koeberling O, Welsch JA, Granoff DM. Protective antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed genome-derived neisserial antigen 1870. J Infect Dis 2005; 192:580-590.
75. Zollinger WD, Donets M, Brandt BL, et al. Multivalent group B meningococcal vaccine based on native outer membrane vesicles has potential for providing safe, broadly protective immunity. In: Program and abstracts of the 16th International Pathogenic Neisseria Conference (Rotterdam, The Netherlands). 2008. Abstract 035.
76. Cox AD, Zou W, Gidney MA, et al. Candidacy of LPS-based glycoconjugates to prevent invasive meningococcal disease: developmental chemistry and investigation of immunological responses following immunization of mice and rabbits. Vaccine 2005; 23:5045-5054.
77. Plested JS, Harris SL, Wright JC, et al. Highly conserved Neisseria meningitidis inner-core lipopolysaccharide epitope confers protection against experimental meningococcal bacteremia. J Infect Dis 2003; 187:1223-1234.
78. Estabrook MM, Jarvis GA, McLeod Griffiss J. Affinity-purified human immunoglobulin G that binds a lacto-N-neotetraose-depcndent lipooligosaccharide structure is bactericidal for serogroup B Neisseria meningitidis. Infect Immun 2007;75:1025-1033.
79. Zollinger WD, Mandrell RE. Importance of complement source in bactericidal activity of human antibody and murine monoclonal antibody to meningococcal group B polysaccharide. Infect Immun 1983;40:257-264.
80. Santos GF, Deck RR, Donnelly J, Blackwelder W, Granoff DM. Importance of complement source in measuring meningococcal bactericidal titers. Clin Diagn Lab Immunol 2001; 8:616-623.
81. Granoff DM, Welsch JA, Ram S. Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera. Infect Immun 2009; 77:764-769.
82. De Groot AS, Rappuoli R. Genome-derived vaccines. Expert Rev Vaccines 2004; 3:59-76.
83. Capecchi B, Serruto D, Adu-Bobie J, Rappuoli R, Pizza M. The genome revolution in vaccine research. Curr Issues Mol Biol 2004; 6: 17-27.
84. Grifantini R, Sebastian S, Frigimclica E, et al. Identification of ironactivated and -repressed Fur-dependent genes by transcriptome analysis of Neisseria meningitidis group B. Proc Natl Acad Sci U S A 2003; 100:9542-9547.
85. Bernardini G, Braconi D, Lusini P, Santucci A. Postgenomics of Neisseria meningitidis: an update. Expert Rev Proteomics 2009; 6:135-143.
86. Bernardini G, Braconi D, Martelli P, Santucci A. Postgenomics of Neisseria meningitidis for vaccines development. Expert Rev Proteomics 2007;4:667-677.
87. Martin D, Cadieux N, Hamel J, Brodeur BR. Highly conserved Neisseria meningitidis surface protein confers protection against experimental infection. J Exp Med 1997;185:1173-1183.
88. Moe GR, Tan S, Granoff DM. Differences in surface expression of NspA among Neisseria meningitidis group B strains. Infect Immun 1999;67:5664-5675.
89. Halperin SA, Langley JM, Smith B, et al. Phase 1 first-in-human studies of the reactogcnicity and immunogenicity of a recombinant meningococcal NspA vaccine in healthy adults. Vaccine 2007; 25: 450-457.
90. West D, Reddin K, Matheson M, et al. Recombinant Neisseria meningitidis transferrin binding protein A protects against experimental meningococcal infection. Infect Immun 2001;69:1561-1567.
91. Rokbi B, Mignon M, Maitre-Wilmotte G, et al. Evaluation of recombinant transferrin-binding protein B variants from Neisseria meningitidis for their ability to induce cross-reactive and bactericidal antibodies against a genetically diverse collection of serogroup B strains. Infect Immun 1997;65:55-63.
92. Danve B, Lissolo L, Guinet F, et al. Safety and immunogenicity of a Neisseria meningitidis group B transferrin binding protein vaccine in adults. In: Program and abstracts of the 11th International Pathogenic Neisserial Conference (Nice, France). 1998.
93. Perez RE, Lasa AM, Rodriguez RS, Menendez EC, Suarez JG, Balaguer HD. Scale-up of recombinant Ope protein production in Escherichia coli for a meningococcal vaccine. J Biotechnol 2006; 127:109-114.
94. Jolley KA, Appleby L, Wright JC, Christodoulides M, Heckels JE. Immunization with recombinant Ope outer membrane protein from Neisseria meningitidis: influence of sequence variation and levels of expression on the bactericidal immune response against meningococci. Infect Immun 2001;69:3809-3816.
95. Callaghan MJ, Buckee CO, Jolley KA, Kriz P, Maiden MC, Gupta S. The effect of immune selection on the structure of the meningococcal opa protein repertoire. PLoS Pathog 2008;4:e1000020.
96. Giuliani MM, Adu-Bobie J, Comanducci M, et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci U S A 2006; 103: 10834-10839.
97. Plested JS, Granoff DM. Vaccine-induced opsonophagocytic immunity to Neisseria meningitidis group B. Clin Vaccine Immunol 2008; 15:799-804.
98. Jacobsson S, Thulin S, Moiling P, et al. Sequence constancies and variations in genes encoding three new meningococcal vaccine candidate antigens. Vaccine 2006;24:2161-2168.
99. Welsch JA, Moe GR, Rossi R, Adu-Bobie J, Rappuoli R, Granoff DM. Antibody to genome-derived neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity. J Infect Dis 2003;188:1730-1740.
100. Fletcher LD, Bernfield L, Barniak V, et al. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect Immun 2004; 72: 2088-2100.
101. Thompson EA, Feavers IM, Maiden MC. Antigenic diversity of meningococcal enterobactin receptor FetA, a vaccine component. Microbiology 2003;149:1849-1858.
102. Capecchi B, Adu-Bobie J, Di Marcello F, et al. Neisseria meningitidis NadA is a new invasin which promotes bacterial adhesion to and penetration into human epithelial cells. Mol Microbiol 2005; 55: 687-698.
103. Beernink PT, Welsch JA, Harrison LH, Leipus A, Kaplan SL, Granoff DM. Prevalence of factor H-binding protein variants and NadA among meningococcal group B isolates from the United States: implications for the development of a multicomponent group B vaccine. J Infect Dis 2007; 195:1472-1479.
104. Comanducci M, Bambini S, Caugant DA, et al. NadA diversity and carriage in Neisseria meningitidis. Infect Immun 2004;72:4217-4223.
105. Comanducci M, Bambini S, Brunelli B, et al. NadA, a novel vaccine candidate of Neisseria meningitidis. J Exp Med 2002; 195:1445-1454.
106. Grifantini R, Bartolini E, Muzzi A, et al. Previously unrecognized vaccine candidates against group B meningococcus identified by DNA microarrays. Nat Biotechnol 2002;20:914-921.
107. Hou VC, Moe GR, Raad Z, Wuorimaa T, Granoff DM. Conformational epitopes recognized by protective anti-neisserial surface protein a antibodies. Infect Immun 2003;71:6844-6849.
108. Murphy E, Andrew L, Lee KL, et al. Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J Infect Dis 2009; 200: 379-389.
109. Schneider MC, Exley RM, Chan H, et al. Functional significance of factor H binding to Neisseria meningitidis. J Immunol 2006; 176: 7566-7575.
110. Welsch JA, Ram S, Koeberling O, Granoff DM. Complement-dependent synergistic bactericidal activity of antibodies against factor Hbinding protein, a sparsely distributed meningococcal vaccine antigen. J Infect Dis 2008; 197:1053-1061.
111. Seib KL, Serrato D, Oriente F, et al. Factor H-binding protein is important for meningococcal survival in human whole blood and serum and in the presence of the antimicrobial peptide LL-37. Infect Immun 2009; 77:292-299.
112. Haralambous E, Dolly SO, Hibberd ML, et al. Factor H, a regulator of complement activity, is a major determinant of meningococcal disease susceptibility in UK Caucasian patients. Scand J Infect Dis 2006;38:764-771.
113. Schneider MC, Prosser BE, Caesar JJ, et al. Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates. Nature 2009;458:890-893.
114. Beernink PT, Welsch JA, Bar-Lev M, Koeberling O, Comanducci M, Granoff DM. Fine antigenic specificity and cooperative bactericidal activity of monoclonal antibodies directed at the meningococcal vaccine candidate, factor H-binding protein. Infect Immun 2008; 76: 4232-4240.
115. Beernink PT, Granoff DM. Bactericidal antibody responses induced by meningococcal recombinant chimeric factor H-binding protein vaccines. Infect Immun 2008; 76:2568-2575.
116. Beernink PT, Granoff DM. The modular architecture of meningococcal factor H-binding protein. Microbiology 2009; 155:2873-2883.
117. Pajon R, Beernink PT, Harrison LH, Granoff DM. Frequency of factor h-binding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolates. Vaccine 2009 (Epub ahead of print).
118. Jacobsson S, Hedberg ST, Moiling P, et al. Prevalence and sequence variations of the genes encoding the five antigens included in the novel 5CVMB vaccine covering group B meningococcal disease. Vaccine 2009;27:1579-1584.
119. Bambini S, Muzzi A, Olcen P, Rappuoli R, Pizza M, Comanducci M. Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus. Vaccine 2009;27:2794-2803.
120. Plested JS, Welsch JA, Granoff DM. Ex vivo model of meningococcal bacteremia using human blood for measuring vaccine-induced serum passive protective activity. Clin Vaccine Immunol 2009;16:785-791.
121. Richmond P, Marshall H, Nissen MD, et al. A randomized, observerblinded, active control, phase 1 trial of meningococcal serogroup B rLP2086 vaccine in healthy children and adolescents aged 8 to 14 years. In: Program, and abstracts of the 16th International Pathogenic Neisseria Conference (Rotterdam, The Netherlands). 2008. Abstract P212.
122. Marshall H, Nissen MD, Richmond P, et al. A randomized, placebocontrolled, double-blind, phase 1 trial of ascending doses of meningococcal group B rLP2086 vaccine in healthy adults. In: Program and abstracts of the 16th International Pathogenic Neisseria Conference (Rotterdam, The Netherlands). 2008. Abstract P213.
123. Jansen KU, McNeil LK, Dragalin V, et al. Bivalent recombinant LP2086 vaccine to provide broad protection against Neisseria meningitidis B disease: Immunological correlates of protection and how to assess coverage against invasive MnB strains. In: Program and abstracts of the 16th International Pathogenic Neisseria Conference (Rotterdam, The Netherlands). 2008. Abstract 064.
124. Rappuoli R. The application of reverse vaccinology, Novartis MenB vaccine developed by design. In. Program and abstracts of the 16th International Pathogenic Neisseria Conference (Rotterdam, The Netherlands). 2008. Abstract 065.
125. Snape MD, Dawson T, Morant A, et al. Immunogenicity and reactogenicity of a novel serogroup B Neisseria meningitidis vaccine administered from 6 months of age. In: Program and abstracts of the 16th International Pathogenic Neisseria Conference (Rotterdam, The Netherlands). 2008. Abstract 069.
126. Maiden MC, Ibarz-Pavon AB, Urwin R, et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis 2008; 197:737-743.
127. Beernink PT, Caugant DA, Welsch JA, Koeberling O, Granoff DM. Meningococcal factor H-binding protein variants expressed by epidemic capsular group A, W-135, and X strains from Africa. J Infect Dis 2009; 199:1360-1368.
128. de Kleijn ED, de Groot R, Lafeber AB, et al. Prevention of meningococcal serogroup B infections in children: a protein-based vaccine induces immunologic memory. J Infect Dis 2001; 184:98-102.
129. van der Voort ER, van der Ley P, van der Biezen J, et al. Specificity of human bactericidal antibodies against PorA Pl.7,16 induced with a hexavalent meningococcal outer membrane vesicle vaccine. Infect Immun 1996;64:2745-2751.